Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

Background: Anti‐tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti‐TNF therapy with adalimumab (ADA) or infliximab (IFX)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2012-11, Vol.18 (11), p.2043-2055
Hauptverfasser:	Sussman, Daniel A., Kubiliun, Nisa, Mulani, Parvez M., Chao, Jingdong, Gillis, Carol A.T., Yang, Mei, Lu, Mei, T. Abreu, Maria
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adult Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - economics Antirheumatic Agents - therapeutic use Costs Crohn Disease - drug therapy Crohn Disease - economics Crohn's disease Disease Management Drug therapy Female Follow-Up Studies Health Care Costs healthcare costs Hospitalization - economics Humans Infliximab Male Medical research Middle Aged Retrospective Studies Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!